Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + Nivolumab in Osteosarcoma
NCT04803877Phase 2Active, not recruiting
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Start
- Jun 2021
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in osteosarcoma (OS), sponsored by Sarcoma Alliance for Research through Collaboration. Started Jun 2021; status: active, not recruiting.
02
Drugs
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT04803877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04803877.